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To the Editor
The current coronavirus disease 2019 
(COVID-19) pandemic has caused millions of 
cases worldwide and is still creating havoc all 
around the world. The novel coronavirus mainly 
affects the lungs and causes severe disease in 
the form of acute respiratory distress syndrome. 
These patients are at an additional risk of devel-
oping pulmonary thromboembolism owing to 
multiple mechanisms such as endothelial injury, 
coagulopathy, and vasculopathy due to virus re-
lated damage [1]. COVID convalescent plasma is 
presently being used extensively in the treatment 
of severe cases [2, 3]. It has shown promising 
results in COVID-19 cases, but has an additional 
risk factor of being highly prothrombotic which 
predisposes these patients to pulmonary thrombo-
embolism [4, 5]. This has rarely been reported in 
literature. Herein, we present a case of a patient 
with severe COVID-19 disease who developed 
pulmonary thromboembolism post-convalescent 
plasma administration while he was on a thera-
peutic dose of heparin.
A 60-year-old male, who had also been di-
agnosed with primary hypertension for 5 years 
(well-controlled on oral antihypertensives), 
bronchial asthma for 30 years (well-controlled 
on inhaled bronchodilators and inhaled cortico-
steroids), and benign prostatic hyperplasia for 
5 years (treated with oral alpha-blockers), report-
ed with a history of moderate grade fever and 
cough of 4 days duration. He also complained of 
dyspnoea on rest that had been present for 1 day. 
He was diagnosed with COVID-19 infection 
after a nasopharyngeal throat swab and reverse 
transcriptase-polymerase chain reaction (RT- 
-PCR) testing. At presentation, he was hypoxic on 
room air (80%), had a pO2/FiO2 < 100, and was 
managed via high flow nasal cannula (flow — 
60 L/min and FiO2 — 100%). His chest roent-
genogram showed bilateral peripheral air-space 
opacities involving bilateral mid- and lower 
zones (Figure 1). He was concurrently initiated 
on injectable steroids (IV methylprednisolone, 
1 mg/kg twice daily), antibiotics (iv ceftriaxone 
and levofloxacin), and a therapeutic dose of 
low-molecular-weight heparin (60 mg subcuta-
neously, twice daily). He had further deteriora-
tion and he was diagnosed as having cytokine 
storm syndrome based on increased inflammato-
ry markers (C-reactive protein, ferritin, D-dimer, 
lactate dehydrogenase, and interleukin-6) and an 
increased requirement for oxygen. We managed 
him with 2 doses of an anti-IL6 agent (tocilizum-
ab, 8 mg/kg) and 2 doses of COVID convalescent 
plasma (CCP) at 200 ml per dose. He showed 
a significant response with improvement in 
clinical, radiological, and lab parameters. How-
ever, after 12 hours of CCP therapy, he showed 
deterioration with an increased requirement for 
oxygen. He was hypoxic and it was becoming 
difficult to wean him off oxygen. In view of 
a suspicion of pulmonary thromboembolism 
and a raised D-dimer level (> 20 ng/mL), he 
underwent a computed tomography pulmonary 
angiogram which showed subsegmental thrombi 
in the right lower lobe and segmental thrombi in 
the left upper lobe which confirmed our suspi-
cion (Figure 2). Since he was normotensive, he 
was continued on therapeutic heparin and later 
discharged on oral anti-coagulants. Currently, 
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Figure 1. Chest skiagram showing bilateral mid- and lower zone airspace opacities
Figure 2. A. Computed tomography of pulmonary angiogram showing subsegmental thrombi in the right lower lobe and segmental thrombi in the 
left upper lobe
A
his condition has improved and he is able to 
maintain saturation on room air. 
The present COVID-19 pandemic has been 
implicated in causing an immense prothrombotic 
state in affected patients which can cause an 
increased risk of pulmonary thromboembolism 
even when they are on prophylactic LMWH 
[1]. The pathophysiology includes endothelial 
inflammation, complement activation, throm-
bin generation, and platelet and leukocyte re-
cruitment. These patients warrant prophylactic 
heparin to prevent this catastrophe [1]. COVID 
convalescent plasma has emerged as a potential 
therapy for severe COVID-19 patients [2–4]. How-
ever these patients are at a higher risk of pulmo-
nary thromboembolism post COVID convalescent 
plasma therapy, which is rarely reported. These 
patients are already in a dysregulated coagula-
tive state and the administration of convalescent 
plasma can tip the balance towards a catastrophic 
event like pulmonary thromboembolism [5, 6]. 
Thus COVID-19 convalescent plasma therapy 
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Figure 2. B–C. Computed tomography of pulmonary angiogram showing subsegmental thrombi in the right lower lobe and segmental thrombi in 
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